Slingshot members are tracking this event:

Aimmune (AIMT) Expects to Complete Enrollment for Phase 3 PALISADE Trial Evaluating AR101 in Peanut Allergies in H2 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 20, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Palisade Trial, Complete Enrollment, H2 2016, Peanut Allergies